Management of Menstrual Disorders in Thyroid Disease

Initial Diagnostic Evaluation

The American College of Clinical Endocrinologists recommends measuring TSH and free T4 to confirm the diagnosis and severity of thyroid disease, with a target TSH within the normal reference range (0.4-4.5 mIU/L) 2
The American Academy of Family Physicians suggests obtaining a pregnancy test in all reproductive-age women, regardless of reported contraceptive use, to rule out pregnancy as a cause of menstrual irregularities 3
The Endocrine Society recommends checking prolactin levels, as hypothyroidism can cause hyperprolactinemia and galactorrhea through TRH-mediated prolactin release 4
The American College of Obstetricians and Gynecologists advises measuring LH, FSH (day 3-6 of cycle), and mid-luteal progesterone (<6 nmol/L indicates anovulation) to assess ovulatory status 4, 5
Pelvic ultrasound (transvaginal preferred) should be considered if hormonal tests suggest ovarian pathology or to exclude structural causes (polyps, fibroids, adenomyosis) 4, 3

The American Thyroid Association recommends initiating levothyroxine at 1.6 mcg/kg/day for patients without cardiac risk factors (age <70, no cardiac disease, not frail) to normalize thyroid function and resolve menstrual irregularities 2
The American College of Clinical Endocrinologists suggests that menstrual cycles typically normalize within 2-5 days of achieving adequate thyroid hormone replacement, with complete resolution of heavy bleeding within one week 1
For patients with persistent heavy bleeding, the American Academy of Family Physicians recommends first-line treatment with NSAIDs, such as mefenamic acid 500 mg three times daily for 5 days during bleeding episodes 1, 5, 3
The Endocrine Society advises avoiding aspirin, as it may increase blood loss in women with baseline menstrual blood loss <60 mL 6, 5
Tranexamic acid is recommended as a second-line treatment, significantly reducing menstrual blood loss compared to placebo, but is contraindicated in women with active thromboembolic disease or history/risk of thrombosis 6, 5
Short-term hormonal therapy, such as low-dose combined oral contraceptives, may be considered as a third-line treatment, but increases venous thromboembolism risk 3-4 fold 1, 3
The American College of Obstetricians and Gynecologists recommends levonorgestrel-releasing IUD as a long-term option, reducing menstrual blood loss by 71-95% 5, 3

The American Thyroid Association notes that certain antiepileptic drugs (valproate, carbamazepine, phenytoin) can worsen menstrual irregularities and affect SHBG levels 4, 5
The Endocrine Society recommends reviewing all medications that may impact reproductive hormones 4
When menstrual irregularities persist despite euthyroid state, the American Academy of Family Physicians suggests reassessing for structural pathology (polyps, fibroids, adenomyosis, endometrial hyperplasia) and evaluating for PCOS (affects 4-6% of women) 7, 3, 1, 5
The American College of Clinical Endocrinologists advises referring to gynecology if bleeding persists despite two treatment attempts 3
The American Thyroid Association recommends monitoring response to treatment, reassessing menstrual pattern within 1-2 cycles of initiating symptomatic bleeding management, and continuing to monitor TSH every 6-12 months once stable on thyroid replacement 1, 3